Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-World QL1706-Based Therapy for Solid Tumors
ChiCTR2400093989Phase 4Not yet recruiting
- Sponsor
- Nantong Cancer Hospital
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1706 in Nonhematologic neoplasms, sponsored by Nantong Cancer Hospital. Primary endpoint: Safety. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2400093989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093989.